CHENGDA PHARMA(301201)2025-01-08 09:26Group 1: Stem Cell Projects - The company has established a technical collaboration with Chiron Pharma, Inc. for two stem cell projects targeting heart attack and post-stroke conditions, both of which have received FDA clinical approval [2] - The heart attack project has completed Phase I clinical trials and is currently in Phase II, while the stroke project is in Phase I/IIa clinical trials [2] - The stem cells used are mesenchymal stem cells derived from umbilical cords, which have good expansion capabilities and maintain their differentiation potential [3] Group 2: Clinical Trial Results - Phase I study results for the heart attack indication show that the combination of intracoronary and intravenous administration is safe and well-tolerated, with all reported adverse events being mild to moderate [3] - No significant clinical changes were observed from baseline during the trials, indicating good safety characteristics [3] Group 3: Business Development and Orders - The company is actively enhancing its market development efforts and has a good order backlog, aiming for stable growth in both domestic and international sales [3] - The company is expanding its product line in the active pharmaceutical ingredient (API) sector, focusing on central nervous system drugs, cardiovascular drugs, and other therapeutic areas [3] - The company has received regulatory approvals for several APIs, including L-carnitine and has obtained European CEP certification, covering major global market quality standards [3] Group 4: Future Plans - The company is strategically positioning itself in the biopharmaceutical sector, particularly in cell-based therapies, to create a second growth curve for its performance [3] - Ongoing renovations for the new facility in Shanghai are aimed at supporting the stem cell project, with plans for further research and clinical trials [3] Group 5: Disclosure Information - The investor relations activity did not involve any undisclosed significant information [3]